Published in Clin Pharmacol Ther on October 01, 1999
Improvement in the handling of drug-drug interactions. Eur J Clin Pharmacol (2008) 0.80
What is the true risk of a pharmacokinetic drug-drug interaction? Eur J Clin Pharmacol (2007) 0.75
Linear modeling of mRNA expression levels during CNS development and injury. Pac Symp Biocomput (1999) 3.07
A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A (2001) 2.93
A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest (1999) 2.91
Infection of immunocompromised patients by avian H9N2 influenza A virus. J Infect (2011) 2.29
Cluster analysis and data visualization of large-scale gene expression data. Pac Symp Biocomput (1998) 2.20
A gene expression profile of Alzheimer's disease. DNA Cell Biol (2001) 2.16
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut (2011) 2.14
Comparison of activated charcoal and ipecac syrup in prevention of drug absorption. Eur J Clin Pharmacol (1983) 2.09
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (1998) 2.09
Should the cement mantle around the femoral component be thick or thin? J Bone Joint Surg Br (2003) 2.05
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 2.01
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther (1998) 1.99
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2007) 1.96
Developmental kinetics of GAD family mRNAs parallel neurogenesis in the rat spinal cord. J Neurosci (1995) 1.94
Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clin Pharmacokinet (1983) 1.89
Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol (1979) 1.82
Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin-8 promoter. The role of Oct-1 as a transcriptional repressor. J Biol Chem (1997) 1.82
Genomic analysis of the Hsp70 superfamily in Arabidopsis thaliana. Cell Stress Chaperones (2001) 1.73
Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet (1993) 1.70
Purification, cloning, and characterization of the CEL I nuclease. Biochemistry (2000) 1.68
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther (2009) 1.67
Effect of diuretic, beta-adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: a cross-over study. Br J Clin Pharmacol (1978) 1.62
Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther (1997) 1.59
Haemodynamic and catecholamine responses to induction of anaesthesia and tracheal intubation: comparison between propofol and thiopentone. Br J Anaesth (1993) 1.54
Local infiltration analgesia with levobupivacaine compared with intrathecal morphine in total hip arthroplasty patients. Acta Anaesthesiol Scand (2012) 1.53
The variability of serological and molecular diagnosis of feline immunodeficiency virus infection. Can Vet J (2004) 1.52
Acute oxalate nephropathy after ingestion of star fruit. Am J Kidney Dis (2001) 1.51
Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. Int J Clin Pharmacol Ther Toxicol (1985) 1.50
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther (1998) 1.49
Histopathological study of Sauropus androgynus-associated constrictive bronchiolitis obliterans: a new cause of constrictive bronchiolitis obliterans. Am J Surg Pathol (1997) 1.48
A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther (1993) 1.45
Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther (1998) 1.42
Intestinal inflammation reduces expression of DRA, a transporter responsible for congenital chloride diarrhea. Am J Physiol (1998) 1.41
Cyclosporine A increases plasma concentrations and effects of repaglinide. Am J Transplant (2006) 1.40
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther (2001) 1.40
Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther (1996) 1.39
Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol (1980) 1.38
Observation of an antimatter hypernucleus. Science (2010) 1.38
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 1.38
The incidence of active tuberculosis in a large urban area. Am J Epidemiol (1989) 1.35
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther (1999) 1.34
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol (1998) 1.33
Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther (1991) 1.32
The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg (1996) 1.31
Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 1.30
Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. Eur J Clin Pharmacol (1978) 1.29
Interactions with the absorption of tetracyclines. Drugs (1976) 1.29
Sotalol and prolonged Q-Tc interval. Lancet (1981) 1.27
The application of shannon entropy in the identification of putative drug targets. Biosystems (2000) 1.27
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia (2003) 1.27
Interference of iron with the absorption of tetracyclines in man. Br Med J (1970) 1.25
Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther (2000) 1.24
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol (1998) 1.24
Cellular uptake of amelogenin, and its localization to CD63, and Lamp1-positive vesicles. Cell Mol Life Sci (2007) 1.23
Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology (2007) 1.22
Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol (2002) 1.22
Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J Neurosci (1999) 1.22
Bioavailability and central side effects of different carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol (1985) 1.22
Prolongation of the Q-T interval caused by sotalol--possible association with ventricular tachyarrhythmias. Eur Heart J (1981) 1.20
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther (2001) 1.19
Drug-related deaths in a university central hospital. Eur J Clin Pharmacol (2002) 1.18
The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG (2000) 1.17
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther (2007) 1.16
Itraconazole decreases renal clearance of digoxin. Ther Drug Monit (1997) 1.16
Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis (1997) 1.15
Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther (1998) 1.13
Biodegradation and biocompatability of a calcium sulphate-hydroxyapatite bone substitute. J Bone Joint Surg Br (2004) 1.12
Inhibitory effect of various iron salts on the absorption of tetracycline in man. Eur J Clin Pharmacol (1974) 1.11
Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol (1994) 1.11
Ocular manifestations of tuberculosis. Ophthalmology (2001) 1.10
Helium ion microscopy for high-resolution visualization of the articular cartilage collagen network. J Microsc (2012) 1.10
Acupuncture therapy for the symptoms of Parkinson's disease. Mov Disord (2002) 1.09
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol (2001) 1.08
Infection of the fetus with hepatitis B e antigen via the placenta. Lancet (2000) 1.06
Comment on 'Temperature dependent optical properties of PbS nanocrystals'. Nanotechnology (2013) 1.06
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia (2003) 1.06
An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis (1996) 1.05
Sotalol intoxication with prolonged Q-T interval and severe tachyarrhythmias. Br Med J (1979) 1.05
Intrarenal mixed germ cell tumor. J Urol (2000) 1.05
Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother (2001) 1.05
Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol (1981) 1.05
Intracellular oxidative stress and cadmium ions release induce cytotoxicity of unmodified cadmium sulfide quantum dots. Toxicol In Vitro (2009) 1.04
Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother (1992) 1.04
Stereospecificity in some central and circulatory effects of phenylisopropyl-adenosine (PIA). Arzneimittelforschung (1975) 1.04
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos (2001) 1.04
Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos (2000) 1.04